Drugs / PF06263276
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02193815 | Sep 2014 → Feb 2015 | psoriasis | Pfizer | Completed | Missed primary |
| Phase 1 | NCT01981681 | Nov 2013 → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF06263276 | “PF-06263276 is a first in class inhibitor of the Janus kinase (JAK) enzymes 1, 2, 3 and tyrosine kinase 2 (TYK2)” NCT01981681 ↗ |
| Action | Inhibit | “first in class inhibitor of the Janus kinase (JAK) enzymes 1, 2, 3 and tyrosine kinase 2 (TYK2)” NCT01981681 ↗ |
| Modality | Small molecule | — CHEMBL3644620 ↗ |
| Route | Topical | “Topically Applied PF-06263276” NCT01981681 ↗ |
| Target | TYK2 | “inhibitor of the Janus kinase (JAK) enzymes 1, 2, 3 and tyrosine kinase 2 (TYK2)” NCT01981681 ↗ |